| Therapeutic | Tremelimumab |
| Target | CTLA4 |
| Heavy Chain | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPRGATLYYYYYGMDVWGQGTTVTVSS |
| Light Chain | DIQMTQSPSSLSASVGDRVTITCRASQSINSYLDWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYSTPFTFGPGTKVEIK |
| 100% seqID Fv Structure | 5ggu [Fvs: AB, HL], 5ggv [Fvs: HL] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 5ggu [Fvs: AB, HL] |
| 100% seqID Structure | 5ggv [Fvs: HL] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G2 |
| Highest Clinical Trial (Feb '25) | Phase-III |
| Estimated Status (Feb '25) | Active |
| Recorded Developmental Technology | Abgenix XenoMouse |
| INN Year Proposed | 2005 |
| INN Year Recommended | 2008 |
| Companies Involved | AIO Studien gGmbH, Amgen, ARCAGY/GINECO Group, AstraZeneca, Azienda Ospedaliera Universitaria Senese, Canadian Cancer Trials Group, Charite - Universitatsmedizin Berlin, Dana-Farber Cancer Institute, Fondazione IRCCS Istituto Nazionale dei Tumori, Grupo Espanol de Tumores Neuroendocrinos, Hoosier Cancer Research Network, Immunocore, Institute Gustave-Roussy, Kyoto Breast Cancer Research Network, M. D. Anderson Cancer Center, MedImmune, Memorial Sloan-Kettering Cancer Center, National Cancer Institute (USA), Northwestern University, Pfizer, Seoul National University Hospital, UNICANCER, University College London, University of Maryland Greenbaum Cancer Center, Yonsei University College of Medicine |
| Conditions Approved | na |
| Conditions Active | Head and neck cancer, Liver cancer, Mesothelioma, Non-small cell lung cancer, Renal cell carcinoma, Small cell lung cancer, Solid tumours, Urogenital cancer, Biliary cancer, Bladder cancer, Breast cancer, Cholangiocarcinoma, Colorectal cancer, Endometrial cancer, Fallopian tube cancer, Gallbladder cancer, Gastric cancer, Gastrointestinal cancer, Germ cell and embryonal neoplasms, Glioblastoma, Lung cancer, Neuroendocrine tumours, Oropharyngeal cancer, Ovarian cancer, Pancreatic cancer, Peritoneal cancer, Prostate cancer, Sarcoma, Soft tissue sarcoma, Thyroid cancer, Haematological malignancies, Malignant melanoma, Oesophageal cancer, Cervical cancer, Diffuse large B cell lymphoma, Gynaecological cancer, Myelodysplastic syndromes, Vulvovaginal cancer |
| Conditions Discontinued | na |
| Notes | Tremelimumab and Ticilimumab are the same mAb |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
